BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 12529742)

  • 1. Should patients with deep vein thrombosis alone be treated as those with concomitant asymptomatic pulmonary embolism? A prospective study.
    Monreal M; Büller H; Lensing AW; Bonet M; Roncales J; Muchart J; Fraile M
    Thromb Haemost; 2002 Dec; 88(6):938-42. PubMed ID: 12529742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymptomatic pulmonary embolism.
    Jiménez D; Díaz G; Marín E; Vidal R; Sueiro A; Yusen RD
    Thromb Haemost; 2006 Mar; 95(3):562-6. PubMed ID: 16525588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism.
    Wells PS; Anderson DR; Rodger MA; Forgie MA; Florack P; Touchie D; Morrow B; Gray L; O'Rourke K; Wells G; Kovacs J; Kovacs MJ
    Arch Intern Med; 2005 Apr; 165(7):733-8. PubMed ID: 15824291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once- or twice-daily low-molecular-weight heparin.
    Partsch H; Kechavarz B; Mostbeck A; Köhn H; Lipp C
    J Vasc Surg; 1996 Nov; 24(5):774-82. PubMed ID: 8918323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Kearon C; Kahn SR; Agnelli G; Goldhaber S; Raskob GE; Comerota AJ
    Chest; 2008 Jun; 133(6 Suppl):454S-545S. PubMed ID: 18574272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective study on the usefulness of lung scan in patients with deep vein thrombosis of the lower limbs.
    Monreal M; Ruiz J; Fraile M; Bonet M; Davant E; Muchart J; Vallejos V
    Thromb Haemost; 2001 May; 85(5):771-4. PubMed ID: 11372666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis.
    Belcaro G; Nicolaides AN; Cesarone MR; Laurora G; De Sanctis MT; Incandela L; Barsotti A; Corsi M; Vasdekis S; Christopoulos D; Lennox A; Malouf M
    Angiology; 1999 Oct; 50(10):781-7. PubMed ID: 10535716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low molecular weight heparin for deep vein thrombosis in glioma patients.
    Schmidt F; Faul C; Dichgans J; Weller M
    J Neurol; 2002 Oct; 249(10):1409-12. PubMed ID: 12382158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis.
    Fiessinger JN; Lopez-Fernandez M; Gatterer E; Granqvist S; Kher A; Olsson CG; Söderberg K
    Thromb Haemost; 1996 Aug; 76(2):195-9. PubMed ID: 8865530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Pinede L, Ninet J, Duhaut P et al for the Investigators of the 'Durée Optimale du Traitement Antivitamines K' (DOTAVK) study. Circulation 2001; 103: 2453-60.
    Anand SS
    Vasc Med; 2001 Nov; 6(4):269-70. PubMed ID: 11958396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evolution in the pharmacological treatment of venous thrombosis according to evidence-based medicine].
    Manganaro A; Giannino D; Lembo D; Bruni F; Consolo F
    Minerva Cardioangiol; 2000 Dec; 48(12 Suppl 1):41-51. PubMed ID: 11253339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of once-daily dose of low-molecular-weight heparin to prevent venous thromboembolism in multisystem trauma patients.
    Cothren CC; Smith WR; Moore EE; Morgan SJ
    World J Surg; 2007 Jan; 31(1):98-104. PubMed ID: 17180563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outpatient treatment of pulmonary embolism with dalteparin.
    Kovacs MJ; Anderson D; Morrow B; Gray L; Touchie D; Wells PS
    Thromb Haemost; 2000 Feb; 83(2):209-11. PubMed ID: 10739374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M;
    N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary prevention of venous thromboembolism: A role for low-molecular-weight heparin.
    Monreal M; Roncales FJ; Ruiz J; Muchart J; Fraile M; Costa J; Hernandez JA
    Haemostasis; 1998; 28(5):236-43. PubMed ID: 10420072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
    Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
    Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Home therapy with LMWH in deep vein thrombosis: randomized study comparing single and double daily administrations.
    Bellosta R; Ferrari P; Luzzani L; Carugati C; Cossu L; Talarico M; Sarcina A
    Angiology; 2007; 58(3):316-22. PubMed ID: 17626986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical analysis of 20 pregnant women with venous thromboembolic disease].
    Sun P; Dong DN
    Zhonghua Fu Chan Ke Za Zhi; 2011 Dec; 46(12):911-6. PubMed ID: 22333281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors.
    Cook D; Douketis J; Meade M; Guyatt G; Zytaruk N; Granton J; Skrobik Y; Albert M; Fowler R; Hebert P; Pagliarello G; Friedrich J; Freitag A; Karachi T; Rabbat C; Heels-Ansdell D; Geerts W; Crowther M;
    Crit Care; 2008; 12(2):R32. PubMed ID: 18315876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis.
    Luomanmäki K; Grankvist S; Hallert C; Jauro I; Ketola K; Kim HC; Kiviniemi H; Koskivirta H; Sörskog L; Vilkko P
    J Intern Med; 1996 Aug; 240(2):85-92. PubMed ID: 8810934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.